United States Biotechnology & Medical Research

OncoMed Pharmaceuticals Inc (OMED)

Track

Track

Ticker: OMED Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Gurney Austin See Remarks Officer
Transaction date
Sale
Price
52.20
Quantity 47,495 -25.6%
Value US$4,213,318
Li Yvonne See Remarks Officer
Transaction date
Sale
Price
320.79
Quantity 48,320 -4.0%
Value US$1,028,784
Stagg Robert SVP, Clinical R&D Officer
Transaction date
Sale
Price
364.93
Quantity 92,249 -0.0%
Value US$903,219
Lewicki John A. President & CEO Executive Director
Transaction date
Sale
Price
2.01
Quantity 1,156 -2.0%
Value US$2,324
Hager Alicia J. SVP & General Counsel Officer
Transaction date
Sale
Price
2.02
Quantity 1,156 -2.2%
Value US$2,335
Gurney Austin See Remarks Officer
Transaction date
Sale
Price
2.01
Quantity 1,156 -1.5%
Value US$2,324
Stagg Robert SVP, Clinical R&D Officer
Transaction date
Sale
Price
2.13
Quantity 1,686 -3.9%
Value US$3,589
Li Yvonne See Remarks Officer
Transaction date
Planned sale
Price
2.13
Quantity 1,229 -2.0%
Value US$2,616
Gurney Austin See Remarks Officer
Transaction date
Planned sale
Price
2.13
Quantity 1,686 -2.1%
Value US$3,589
Lewicki John A. President & CEO Executive Director
Transaction date
Planned sale
Price
2.13
Quantity 2,296 -3.9%
Value US$4,888
Hager Alicia J. SVP & General Counsel Officer
Transaction date
Sale
Price
2.13
Quantity 1,686 -3.1%
Value US$3,589
Stagg Robert SVP, Clinical R&D
Transaction date
Sale
Price
2.68
Quantity 4,051 -8.6%
Value US$10,848
Lewicki John A. President & CEO Executive Director
Transaction date
Sale
Price
2.68
Quantity 4,557 -7.6%
Value US$12,202
Gurney Austin See Remarks
Transaction date
Sale
Price
2.68
Quantity 4,051 -5.0%
Value US$10,848
Li Yvonne See Remarks
Transaction date
Sale
Price
2.68
Quantity 5,062 -7.8%
Value US$13,555
Hager Alicia J. SVP & General Counsel
Transaction date
Sale
Price
2.68
Quantity 4,051 -6.9%
Value US$10,848
Hager Alicia J. SVP & General Counsel
Transaction date
Sale
Price
4.24
Quantity 1,202 -2.0%
Value US$5,099
Hager Alicia J. SVP & General Counsel
Transaction date
Sale
Price
4.26
Quantity 46 -0.1%
Value US$196
Patel Sunil See Remarks
Transaction date
Sale
Price
4.24
Quantity 1,202 -1.7%
Value US$5,099
3.9
Patel Sunil See Remarks
Transaction date
Sale
Price
4.27
Quantity 46 -0.1%
Value US$196
HASTINGS PAUL J Chairman & CEO
Transaction date
Sale
Price
4.24
Quantity 1,346 -1.7%
Value US$5,709
2.8
HASTINGS PAUL J Chairman & CEO
Transaction date
Sale
Price
4.26
Quantity 52 -0.1%
Value US$222
Gurney Austin See Remarks
Transaction date
Sale
Price
4.24
Quantity 1,202 -1.5%
Value US$5,099
Gurney Austin See Remarks
Transaction date
Sale
Price
4.27
Quantity 46 -0.1%
Value US$196
Lewicki John A. EVP, Research & Development
Transaction date
Sale
Price
4.24
Quantity 1,202 -1.7%
Value US$5,099
Lewicki John A. EVP, Research & Development
Transaction date
Sale
Price
4.26
Quantity 46 -0.1%
Value US$196
KARSEN PERRY A
Transaction date
Purchase
Price
3.46
Quantity 10,000 +inf%
Value US$34,588
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.70
Quantity 3,222 -100.0%
Value US$11,927
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.70
Quantity 6,358 -100.0%
Value US$23,536
LASERSOHN JACK W Non-Executive Director
Transaction date
Purchase
Price
3.37
Quantity 34,614 +22.9%
Value US$116,639
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.72
Quantity 1,447 -31.0%
Value US$5,377
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.72
Quantity 2,853 -31.0%
Value US$10,601
LASERSOHN JACK W Non-Executive Director
Transaction date
Purchase
Price
3.55
Quantity 20,000 +15.3%
Value US$71,000
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.70
Quantity 2,519 -35.0%
Value US$9,324
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.70
Quantity 4,968 -35.0%
Value US$18,388
LASERSOHN JACK W Non-Executive Director
Transaction date
Purchase
Price
3.49
Quantity 23,507 +21.8%
Value US$82,061
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.58
Quantity 2,321 -24.4%
Value US$8,313
ROOT JONATHAN D Non-Executive Director
Transaction date
Sale
Price
3.58
Quantity 4,579 -24.4%
Value US$16,401
3.9
Patel Sunil See Remarks
Transaction date
Sale
Price
9.06
Quantity 5,711 -18.9%
Value US$51,731
Patel Sunil See Remarks
Transaction date
Sale
Price
8.87
Quantity 43 -0.1%
Value US$382
Hoey Timothy SVP, Cancer Biology & Co-CSO
Transaction date
Planned sale
Price
9.06
Quantity 5,711 -9.1%
Value US$51,731
Hoey Timothy SVP, Cancer Biology & Co-CSO
Transaction date
Planned sale
Price
8.87
Quantity 43 -0.1%
Value US$381
Hager Alicia J. SVP & General Counsel
Transaction date
Sale
Price
9.06
Quantity 4,284 -16.6%
Value US$38,805
Hager Alicia J. SVP & General Counsel
Transaction date
Sale
Price
8.87
Quantity 32 -0.1%
Value US$284
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
9.06
Quantity 6,425 -16.5%
Value US$58,199
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
8.87
Quantity 48 -0.1%
Value US$426
Gurney Austin See Remarks
Transaction date
Planned sale
Price
9.06
Quantity 5,711 -11.7%
Value US$51,731
Gurney Austin See Remarks
Transaction date
Planned sale
Price
8.87
Quantity 43 -0.1%
Value US$381
Lewicki John A. EVP, Research & Development
Transaction date
Planned sale
Price
9.06
Quantity 5,711 -19.9%
Value US$51,731
Lewicki John A. EVP, Research & Development
Transaction date
Planned sale
Price
8.87
Quantity 43 -0.1%
Value US$381
Hager Alicia J. SVP & General Counsel
Transaction date
Planned sale
Price
10.00
Quantity 6,652 -20.4%
Value US$66,520
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
8.52
Quantity 21,369 -36.4%
Value US$181,957
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
8.17
Quantity 21,369 -36.4%
Value US$174,602
Hoey Timothy SVP, Cancer Biology & Co-CSO
Transaction date
Planned sale
Price
7.64
Quantity 12,763 -17.3%
Value US$97,448
Lewicki John A. EVP, Research & Development
Transaction date
Planned sale
Price
7.63
Quantity 9,175 -22.5%
Value US$70,045
Hoey Timothy SVP, Cancer Biology & Co-CSO Officer
Transaction date
Planned sale
Price
9.89
Quantity 12,500 -17.0%
Value US$123,609
Dupont Jakob SVP & Chief Medical Officer Officer
Transaction date
Planned sale
Price
20.01
Quantity 2,500 -10.8%
Value US$50,021
Patel Sunil See Remarks Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
Lewicki John A. EVP & Chief Scientific Officer Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
Dupont Jakob SVP & Chief Medical Officer Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
Hoey Timothy SVP, Cancer Biology Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
Gurney Austin See Remarks Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
Hager Alicia J. VP & General Counsel Officer
Transaction date
Sale
Price
21.33
Quantity 1 -0.0%
Value US$21
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
21.54
Quantity 77 -0.3%
Value US$1,659
Patel Sunil See Remarks Officer
Transaction date
Sale
Price
21.65
Quantity 69 -0.4%
Value US$1,494
Lewicki John A. EVP & Chief Scientific Officer Officer
Transaction date
Sale
Price
21.56
Quantity 69 -0.4%
Value US$1,488
Dupont Jakob SVP & Chief Medical Officer Officer
Transaction date
Sale
Price
21.54
Quantity 69 -0.3%
Value US$1,486
Hoey Timothy SVP, Cancer Biology Officer
Transaction date
Sale
Price
21.56
Quantity 69 -0.1%
Value US$1,488
Gurney Austin See Remarks Officer
Transaction date
Sale
Price
21.54
Quantity 69 -0.2%
Value US$1,486
Hager Alicia J. VP & General Counsel Officer
Transaction date
Sale
Price
21.54
Quantity 52 -0.4%
Value US$1,120
2.8
HASTINGS PAUL J Chairman & CEO Executive Director
Transaction date
Planned sale
Price
22.30
Quantity 2,335 -9.6%
Value US$52,072
3.9
Patel Sunil See Remarks Officer
Transaction date
Sale
Price
22.30
Quantity 2,092 -10.5%
Value US$46,653
Lewicki John A. EVP & Chief Scientific Officer Officer
Transaction date
Sale
Price
22.30
Quantity 2,092 -10.5%
Value US$46,653
Dupont Jakob SVP & Chief Medical Officer Officer
Transaction date
Sale
Price
22.30
Quantity 2,092 -9.2%
Value US$46,653
Hoey Timothy SVP, Cancer Biology Officer
Transaction date
Sale
Price
22.30
Quantity 2,092 -4.2%
Value US$46,653
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2018-12-26 2018-12-24 S Sale
Gurney Austin

See Remarks

Officer
47,495 -25.6%
52.20
US$4,213,318 		47,495 -25.6% 52.20 US$4,213,318
2018-10-11 2018-10-10 S Sale Li Yvonne

See Remarks

Officer
48,320 -4.0%
320.79
US$1,028,784 		48,320 -4.0% 320.79 US$1,028,784
2018-10-11 2018-10-10 S Sale Stagg Robert

SVP, Clinical R&D

Officer
92,249 -0.0%
364.93
US$903,219 		92,249 -0.0% 364.93 US$903,219
2018-10-11 2018-10-10 S Sale
Lewicki John A.

President & CEO

Executive Director
1,156 -2.0%
2.01
US$2,324 		1,156 -2.0% 2.01 US$2,324
2018-10-11 2018-10-10 S Sale Hager Alicia J.

SVP & General Counsel

Officer
1,156 -2.2%
2.02
US$2,335 		1,156 -2.2% 2.02 US$2,335
2018-10-11 2018-10-10 S Sale
Gurney Austin

See Remarks

Officer
1,156 -1.5%
2.01
US$2,324 		1,156 -1.5% 2.01 US$2,324
2018-10-10 2018-10-09 S Sale Stagg Robert

SVP, Clinical R&D

Officer
1,686 -3.9%
2.13
US$3,589 		1,686 -3.9% 2.13 US$3,589
2018-10-10 2018-10-09 PlS Planned sale Li Yvonne

See Remarks

Officer
1,229 -2.0%
2.13
US$2,616 		1,229 -2.0% 2.13 US$2,616
2018-10-10 2018-10-09 PlS Planned sale
Gurney Austin

See Remarks

Officer
1,686 -2.1%
2.13
US$3,589 		1,686 -2.1% 2.13 US$3,589
2018-10-10 2018-10-09 PlS Planned sale
Lewicki John A.

President & CEO

Executive Director
2,296 -3.9%
2.13
US$4,888 		2,296 -3.9% 2.13 US$4,888
2018-10-10 2018-10-09 S Sale
Hager Alicia J.

SVP & General Counsel

Officer
1,686 -3.1%
2.13
US$3,589 		1,686 -3.1% 2.13 US$3,589
2018-04-26 2018-04-24 S Sale
Stagg Robert

SVP, Clinical R&D
4,051 -8.6%
2.68
US$10,848 		4,051 -8.6% 2.68 US$10,848
2018-04-26 2018-04-24 S Sale
Lewicki John A.

President & CEO

Executive Director
4,557 -7.6%
2.68
US$12,202 		4,557 -7.6% 2.68 US$12,202
2018-04-26 2018-04-24 S Sale
Gurney Austin

See Remarks
4,051 -5.0%
2.68
US$10,848 		4,051 -5.0% 2.68 US$10,848
2018-04-26 2018-04-24 S Sale Li Yvonne

See Remarks
5,062 -7.8%
2.68
US$13,555 		5,062 -7.8% 2.68 US$13,555
2018-04-26 2018-04-24 S Sale
Hager Alicia J.

SVP & General Counsel
4,051 -6.9%
2.68
US$10,848 		4,051 -6.9% 2.68 US$10,848
2017-10-12 2017-10-10 S Sale
Hager Alicia J.

SVP & General Counsel
1,202 -2.0%
4.24
US$5,099 		1,202 -2.0% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
Hager Alicia J.

SVP & General Counsel
46 -0.1%
4.26
US$196 		46 -0.1% 4.26 US$196
2017-10-12 2017-10-10 S Sale Patel Sunil

See Remarks
1,202 -1.7%
4.24
US$5,099 		1,202 -1.7% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
3.9
Patel Sunil

See Remarks
46 -0.1%
4.27
US$196 		46 -0.1% 4.27 US$196
2017-10-12 2017-10-10 S Sale HASTINGS PAUL J

Chairman & CEO
1,346 -1.7%
4.24
US$5,709 		1,346 -1.7% 4.24 US$5,709
2017-10-12 2017-10-10 S Sale
2.8
HASTINGS PAUL J

Chairman & CEO
52 -0.1%
4.26
US$222 		52 -0.1% 4.26 US$222
2017-10-12 2017-10-10 S Sale Gurney Austin

See Remarks
1,202 -1.5%
4.24
US$5,099 		1,202 -1.5% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
Gurney Austin

See Remarks
46 -0.1%
4.27
US$196 		46 -0.1% 4.27 US$196
2017-10-12 2017-10-10 S Sale
Lewicki John A.

EVP, Research & Development
1,202 -1.7%
4.24
US$5,099 		1,202 -1.7% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale Lewicki John A.

EVP, Research & Development
46 -0.1%
4.26
US$196 		46 -0.1% 4.26 US$196
2017-06-07 2017-06-05 B Purchase KARSEN PERRY A
10,000 +inf%
3.46
US$34,588 		10,000 +inf% 3.46 US$34,588
2017-05-26 2017-05-26 S Sale ROOT JONATHAN D Non-Executive Director
3,222 -100.0%
3.70
US$11,927 		3,222 -100.0% 3.70 US$11,927
2017-05-26 2017-05-26 S Sale ROOT JONATHAN D Non-Executive Director
6,358 -100.0%
3.70
US$23,536 		6,358 -100.0% 3.70 US$23,536
2017-05-26 2017-05-25 B Purchase LASERSOHN JACK W Non-Executive Director
34,614 +22.9%
3.37
US$116,639 		34,614 +22.9% 3.37 US$116,639
2017-05-26 2017-05-24 S Sale ROOT JONATHAN D Non-Executive Director
1,447 -31.0%
3.72
US$5,377 		1,447 -31.0% 3.72 US$5,377
2017-05-26 2017-05-24 S Sale ROOT JONATHAN D Non-Executive Director
2,853 -31.0%
3.72
US$10,601 		2,853 -31.0% 3.72 US$10,601
2017-05-25 2017-05-23 B Purchase LASERSOHN JACK W Non-Executive Director
20,000 +15.3%
3.55
US$71,000 		20,000 +15.3% 3.55 US$71,000
2017-05-22 2017-05-19 S Sale ROOT JONATHAN D Non-Executive Director
2,519 -35.0%
3.70
US$9,324 		2,519 -35.0% 3.70 US$9,324
2017-05-22 2017-05-19 S Sale ROOT JONATHAN D Non-Executive Director
4,968 -35.0%
3.70
US$18,388 		4,968 -35.0% 3.70 US$18,388
2017-05-18 2017-05-16 B Purchase LASERSOHN JACK W Non-Executive Director
23,507 +21.8%
3.49
US$82,061 		23,507 +21.8% 3.49 US$82,061
2017-05-18 2017-05-16 S Sale ROOT JONATHAN D Non-Executive Director
2,321 -24.4%
3.58
US$8,313 		2,321 -24.4% 3.58 US$8,313
2017-05-18 2017-05-16 S Sale ROOT JONATHAN D Non-Executive Director
4,579 -24.4%
3.58
US$16,401 		4,579 -24.4% 3.58 US$16,401
2017-04-05 2017-04-04 S Sale
3.9
Patel Sunil

See Remarks
5,711 -18.9%
9.06
US$51,731 		5,711 -18.9% 9.06 US$51,731
2017-04-05 2017-04-04 S Sale Patel Sunil

See Remarks
43 -0.1%
8.87
US$382 		43 -0.1% 8.87 US$382
2017-04-05 2017-04-04 PlS Planned sale
Hoey Timothy

SVP, Cancer Biology & Co-CSO
5,711 -9.1%
9.06
US$51,731 		5,711 -9.1% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale
Hoey Timothy

SVP, Cancer Biology & Co-CSO
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-04-05 2017-04-04 S Sale
Hager Alicia J.

SVP & General Counsel
4,284 -16.6%
9.06
US$38,805 		4,284 -16.6% 9.06 US$38,805
2017-04-05 2017-04-04 S Sale
Hager Alicia J.

SVP & General Counsel
32 -0.1%
8.87
US$284 		32 -0.1% 8.87 US$284
2017-04-05 2017-04-04 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
6,425 -16.5%
9.06
US$58,199 		6,425 -16.5% 9.06 US$58,199
2017-04-05 2017-04-04 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
48 -0.1%
8.87
US$426 		48 -0.1% 8.87 US$426
2017-04-05 2017-04-04 PlS Planned sale
Gurney Austin

See Remarks
5,711 -11.7%
9.06
US$51,731 		5,711 -11.7% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale
Gurney Austin

See Remarks
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-04-05 2017-04-04 PlS Planned sale
Lewicki John A.

EVP, Research & Development
5,711 -19.9%
9.06
US$51,731 		5,711 -19.9% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale Lewicki John A.

EVP, Research & Development
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-03-17 2017-03-15 PlS Planned sale Hager Alicia J.

SVP & General Counsel
6,652 -20.4%
10.00
US$66,520 		6,652 -20.4% 10.00 US$66,520
2017-01-09 2017-01-06 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
21,369 -36.4%
8.52
US$181,957 		21,369 -36.4% 8.52 US$181,957
2017-01-09 2017-01-05 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
21,369 -36.4%
8.17
US$174,602 		21,369 -36.4% 8.17 US$174,602
2017-01-05 2017-01-03 PlS Planned sale Hoey Timothy

SVP, Cancer Biology & Co-CSO
12,763 -17.3%
7.64
US$97,448 		12,763 -17.3% 7.64 US$97,448
2017-01-05 2017-01-03 PlS Planned sale Lewicki John A.

EVP, Research & Development
9,175 -22.5%
7.63
US$70,045 		9,175 -22.5% 7.63 US$70,045
2016-11-18 2016-11-16 PlS Planned sale Hoey Timothy

SVP, Cancer Biology & Co-CSO

Officer
12,500 -17.0%
9.89
US$123,609 		12,500 -17.0% 9.89 US$123,609
2016-01-12 2016-01-11 PlS Planned sale Dupont Jakob

SVP & Chief Medical Officer

Officer
2,500 -10.8%
20.01
US$50,021 		2,500 -10.8% 20.01 US$50,021
2016-01-08 2016-01-07 S Sale Patel Sunil

See Remarks

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale
Dupont Jakob

SVP & Chief Medical Officer

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale
Gurney Austin

See Remarks

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Hager Alicia J.

VP & General Counsel

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-06 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
77 -0.3%
21.54
US$1,659 		77 -0.3% 21.54 US$1,659
2016-01-08 2016-01-06 S Sale Patel Sunil

See Remarks

Officer
69 -0.4%
21.65
US$1,494 		69 -0.4% 21.65 US$1,494
2016-01-08 2016-01-06 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
69 -0.4%
21.56
US$1,488 		69 -0.4% 21.56 US$1,488
2016-01-08 2016-01-06 S Sale Dupont Jakob

SVP & Chief Medical Officer

Officer
69 -0.3%
21.54
US$1,486 		69 -0.3% 21.54 US$1,486
2016-01-08 2016-01-06 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
69 -0.1%
21.56
US$1,488 		69 -0.1% 21.56 US$1,488
2016-01-08 2016-01-06 S Sale Gurney Austin

See Remarks

Officer
69 -0.2%
21.54
US$1,486 		69 -0.2% 21.54 US$1,486
2016-01-08 2016-01-06 S Sale Hager Alicia J.

VP & General Counsel

Officer
52 -0.4%
21.54
US$1,120 		52 -0.4% 21.54 US$1,120
2016-01-08 2016-01-06 PlS Planned sale
2.8
HASTINGS PAUL J

Chairman & CEO

Executive Director
2,335 -9.6%
22.30
US$52,072 		2,335 -9.6% 22.30 US$52,072
2016-01-08 2016-01-06 S Sale
3.9
Patel Sunil

See Remarks

Officer
2,092 -10.5%
22.30
US$46,653 		2,092 -10.5% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
2,092 -10.5%
22.30
US$46,653 		2,092 -10.5% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale
Dupont Jakob

SVP & Chief Medical Officer

Officer
2,092 -9.2%
22.30
US$46,653 		2,092 -9.2% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
2,092 -4.2%
22.30
US$46,653 		2,092 -4.2% 22.30 US$46,653
Explore more

More insider trading research around OncoMed Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America